OXYTROL FOR WOMEN OTC
Generic Name and Formulations:
Oxybutynin 3.9mg/day; transdermal patch.
Merck Consumer Care, Inc.
Indications for OXYTROL FOR WOMEN:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
≥18yrs: Apply to clean, dry and smooth area on the abdomen, hips, or buttocks. Use 1 patch for 4 days in a row. Remove patch after 4 days and apply new one. Rotate application sites. Dispose properly with sticky sides together.
<18yrs: not recommended.
Male patients. Pain or burning when urinating. Blood in urine. Unexplained lower back or side pain. Cloudy or foul-smelling urine. Stress incontinence. Urinary or gastric retention. Glaucoma.
Consider other causes of frequent urination (eg, UTI, diabetes, early pregnancy). Unexplained weight loss. Hepatic or renal impairment. Reevaluate if condition worsens or no improvement after 2 weeks. Nursing mothers.
Additive effects with alcohol, other anticholinergic drugs. Caution with antibiotics (eg, erythromycin, clarithromycin) or antifungals (eg, ketoconazole, itraconazole).
Local reactions (eg, itching, rash, redness), sleepiness, dizziness, blurry vision.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline